STOCK TITAN

Imunon (IMNN) Financials

IMNN NASDAQ
Trailing 12 months to September 30, 2026
Revenue Not reported for the trailing 12 months
Net Income -$15.0M n/m YoY
EPS (Diluted) Not reported for the trailing 12 months
Operating Cash Flow -$13.9M n/m YoY
Market Cap $3.8M as of Nov 18, 2026
Price / Sales n/m no full year of revenue reported yet
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 1.4x on $2.6M equity, Q3 FY2027

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 18, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2027, ended Sep 30, 2026 Reported Currency USD FYE June

Newest figures come from the 10-Q for Q3 FY2027, filed Nov 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IMNN SEC filings page.

This page shows Imunon, Inc. (IMNN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI IMNN FY2026

The company remains development-stage: losses and cash use narrowed, but the latest balance sheet shows heavier claims against equity.

The net loss narrowed from $35.9M in FY2022 to $14.5M in FY2025, while operating cash flow also improved from -$23.1M to -$13.9M. In FY2025, free cash flow of -$14.2M remained close to operating cash flow, indicating that the reported improvement reflected lower operating cash use rather than a large accounting-only adjustment.

FY2022 revenue of only $500K sat beside research and development spending of $11.7M, showing that the business was investing well ahead of its recorded commercial scale. FY2025 financing cash flow of $17.1M exceeded operating cash use of -$13.9M, meaning reported resources were being supported by financing rather than operations.

The latest balance-sheet shift is pronounced: liabilities increased 106.7% from FY2025 to FY2026 while equity decreased 40.7%, making the capital structure more creditor-heavy. A current ratio of 1.8x provides a different signal from liabilities-to-equity of 2.6x: near-term assets exceed near-term obligations, but total obligations are large relative to the remaining equity base.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Imunon, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The metrics below are current.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA
-$3.4M
QoQn/m

Imunon, Inc.'s EBITDA was -$3.4M in Q3 2027, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$3.8M
QoQn/m
5Y CAGRn/m
10Y CAGRn/m

Imunon, Inc. reported a net loss of $3.8M in Q3 2027. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.64
QoQn/m

Imunon, Inc. earned -$0.64 per diluted share (EPS) in Q3 2027. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Revenue

Not reported for Q3 2027.

Cash & Balance Sheet

Free Cash Flow
-$3.2M

Imunon, Inc. recorded an outflow of $3.2M in free cash flow in Q3 2027, representing a cash shortfall after capex.

Cash & Debt
$4.0M
QoQ-41.2%
5Y CAGR-30.9%
10Y CAGR-0.4%

Imunon, Inc. held $4.0M in cash against $4.9M in long-term debt as of Q3 2027.

Shares Outstanding
6M
QoQ+15.6%

Imunon, Inc. had 6M shares outstanding in Q3 2027. Against the prior quarter it is up 15.6%.

Dividends Per Share

Not reported for Q3 2027.

Margins & Returns

Return on Equity
-143.0%
QoQ-75.8pp
5Y change-133.9pp
10Y change-82.4pp

Imunon, Inc.'s quarterly ROE was -143.0% in Q3 2027: one quarter's net income over shareholder equity, not annualized. Against the prior quarter it is down 75.8 percentage points.

Gross Margin

Not reported for Q3 2027.

Operating Margin

Not reported for Q3 2027.

Net Margin

Not reported for Q3 2027.

Capital Allocation

R&D Spending
$1.8M
QoQ+22.4%
5Y CAGR-6.2%
10Y CAGR-8.2%

Imunon, Inc. invested $1.8M in research and development in Q3 2027. Against the prior quarter it is up 22.4%.

Capital Expenditures
$2K

Imunon, Inc. invested $2K in capex in Q3 2027, funding long-term assets and infrastructure.

Share Buybacks

Not reported for Q3 2027.

IMNN Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IMNN quarterly income statement
MetricQ3'2710-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
R&D Expenses$1.8M$1.5M+19.4%$2.3M+8.0%$2.5M+11.5%$1.9M-42.3%$1.2M-56.5%$2.2M-34.3%$2.2M-37.2%
SG&A Expenses$1.7M$1.3M-13.9%$2.0M-0.6%$1.8M-7.4%$1.6M-5.5%$1.5M-29.8%$2.0M+15.3%$1.9M-20.8%
Operating Income-$3.4M-$2.8Mn/m-$4.3Mn/m-$4.3Mn/m-$3.5Mn/m-$2.8Mn/m-$4.1Mn/m-$4.1Mn/m
EBITDA-$3.4M-$2.7Mn/m-$4.2Mn/m-$4.2Mn/m-$3.4Mn/m-$2.7Mn/m-$4.1Mn/m-$4.1Mn/m
Interest Expense$264K$77KN/AN/AN/AN/AN/AN/A
Net Income-$3.8M-$2.8Mn/m-$4.2Mn/m-$4.2Mn/m-$3.4Mn/m-$2.7Mn/m-$4.1Mn/m-$4.1Mn/m
EPS (Basic)-$0.64-$0.54-$0.84-$1.30-$1.16-$2.15-$3.15-$3.45
EPS (Diluted)-$0.64-$0.54-$0.84-$1.30-$1.16-$2.15-$3.15-$3.45
Diluted Shares (Avg)6M5M5MN/A3M1M1MN/A

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.

IMNN Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IMNN quarterly balance sheet
MetricQ3'2710-QQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$12.0M$15.0M+70.6%$8.0M+16.9%$12.3M+26.5%$9.0M-37.5%$8.8M-9.3%$6.9M-52.1%$9.7M-55.7%
Current Assets$5.8M$8.7M+26.1%$6.6M+30.0%$10.7M+33.9%$7.3M-42.1%$6.9M-9.9%$5.1M-57.9%$8.0M-56.1%
Cash & Equivalents$4.0M$6.9M+45.2%$4.8M+66.9%$8.8M+49.5%$5.3M-49.1%$4.7M-10.9%$2.9M+22.4%$5.9M+0.6%
Short-Term Investments$0$0n/m$0n/m$0n/m$0n/m$0n/m$0-100.0%$0-100.0%
Accounts ReceivableN/AN/AN/A$0n/mN/AN/AN/A$0n/m
Long-Term Investments$0$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$9.4M$10.8M+76.2%$4.7M-27.3%$5.2M-4.5%$4.9M-20.9%$6.1M+3.0%$6.4M+10.0%$5.5M-35.8%
Current Liabilities$4.2M$4.8M-10.1%$4.2M-28.1%$4.6M-3.4%$4.2M-22.9%$5.3M+4.7%$5.8M+20.3%$4.8M-35.2%
Non-Current Liabilities$5.1M$6.0M+642.3%$493K-19.6%$602K-12.3%$708K-6.5%$811K-7.1%$613K-39.2%$687K-39.7%
Long-Term Debt$4.9MN/AN/AN/AN/AN/AN/AN/A
Total Equity$2.6M$4.2M+57.5%$3.4M+643.2%$7.1M+66.4%$4.1M-50.2%$2.7M-28.9%$452K-94.7%$4.2M-68.3%
Retained Earnings-$432.1M-$428.4Mn/m-$425.5Mn/m-$421.3Mn/m-$417.1Mn/m-$413.6Mn/m-$410.9Mn/m-$406.8Mn/m

Not reported in any period shown, so not listed: Inventory, Goodwill.

IMNN Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IMNN quarterly cash flow statement
MetricQ3'2710-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$3.2M-$3.0Mn/m-$4.0Mn/m-$3.7Mn/m-$4.4Mn/m-$3.0Mn/m-$2.8Mn/m-$4.4Mn/m
Depreciation & Amortization$67K$70K-6.7%$70K+5.0%$75K+101.6%$75K+16.8%$75K+9.8%$67K-5.1%$37K-48.0%
Stock-Based CompensationN/AN/A$549K+168.2%N/AN/AN/A$205Kn/mN/A
Capital Expenditures$2KN/AN/A$4K-75.9%$0-100.0%$17Kn/m$260K+2108.9%$15Kn/m
Free Cash Flow-$3.2MN/AN/A-$3.7Mn/m-$4.4Mn/m-$3.0Mn/m-$3.1Mn/m-$4.4Mn/m
Investing Cash Flow-$2KN/AN/A-$4Kn/m$0n/m-$17K-100.2%-$260K-110.9%-$15Kn/m
Financing Cash Flow$419K$10.2M+110.6%-$2K-101.7%$7.2Mn/m$5.0M$4.8M$106K-$3K-110.8%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

IMNN Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IMNN quarterly financial ratios
MetricQ3'2710-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Return on Equity-143.0%-67.2%+35.9pp-126.5%+781.1pp-59.8%+35.8pp-84.0%-24.9pp-103.0%+25.0pp-907.6%-849.6pp-95.6%-59.1pp
Return on Assets-31.2%-18.8%+12.4pp-53.0%+6.8pp-34.4%+7.4pp-38.1%-4.5pp-31.2%+18.2pp-59.8%-25.4pp-41.8%-19.4pp
Current Ratio1.381.82+0.5x1.59+0.7x2.32+0.6x1.73-0.6x1.30-0.2x0.88-1.6x1.67-0.8x
Debt-to-Equity1.86N/AN/AN/AN/AN/AN/AN/A
Liabilities-to-Equity3.582.58+0.3x1.39-12.8x0.74-0.5x1.20+0.4x2.30+0.7x14.18+13.5x1.29+0.7x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Imunon, Inc. IMNN FY2026 N/A N/A N/A $3.8M —
Xenetic Biosciences, Inc. XBIO FY2025 $3.0M -$2.7M -90.1% $3.6M 67/100
CNS Pharmaceuticals, Inc. CNSP FY2025 N/A -$15.9M N/A $6.6M —
NuCana plc NCNA FY2025 N/A -$39.5M N/A $3.5M —
GRI Bio, Inc. GRI FY2025 N/A -$12.0M N/A $2.8M —
Liminatus Pharma, Inc. LIMN FY2025 N/A N/A N/A $3.6M —

Frequently Asked Questions

Yes, Imunon, Inc. (IMNN) paid $0.15 per share in dividends during fiscal year 2026.

Imunon, Inc. (IMNN) had $15.0M in total assets as of fiscal year 2026, including both current and long-term assets.

Imunon, Inc. (IMNN) had 6M shares outstanding as of fiscal year 2026.

Imunon, Inc. (IMNN) had a current ratio of 1.82 as of fiscal year 2026, which is generally considered healthy.

Imunon, Inc. (IMNN) had a liabilities-to-equity ratio of 2.58 as of fiscal year 2026, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2026, because the filing data we hold for that year carries no long-term debt figure.

Imunon, Inc. (IMNN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $3.8M as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Imunon, Inc. (IMNN) has no price-to-sales ratio at the moment: no full year of revenue reported yet. The market capitalization is $3.8M as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Back to top